Clinical Trial Site,
Our Research History
We have done clinical trials for an assortment of neurological conditions for 20 years.
Our Location
Our site is an outpatient center located in Fullerton, North Orange County. The Neurology Center of North Orange is within 20 minutes of John Wayne Airport (SNA), a convenient airport. Parking is free and plentiful in a private lot.
Our Research Staff
We currently have 4 neurologists and one physician’s assistant at our clinic. Our research staff includes our site research director, four clinical research coordinators, three nurses, and two psychologists. Please contact our site director, Sheraz Mossa, for more details.
Resources
We are able to provide services through our affiliate partners upon when required per protocol. Examples include, but are not limited to: radiology scans (X-Ray, MRI 1.5T or 3T, CT, Amyloid PET, Tau PET, CSF/LP), DEXA. We have access to all major tracers used in Alzheimer’s disease screening including florbetapir (Amyvid), florbetaben (NeuraCeq), flutemetamol (Vizamyl), flortaucipir (Tauvid), and MK-6240.
Our PI and Sub-Is are affiliated with Providence St. Jude Medical Center which is 1.5 miles away.
- Multiple exam rooms
- CLIA-Waived Laboratory
- Certified and qualified raters
- Trained certified RN to administer IV
- Certified, experienced phlebotomists
- -20° & -70° Freezers
- Refrigerator drug storage
- Temperature-controlled, double-locked investigational drug storage
- Temperature alert system monitored 24/7/365 with email/text alerts
- Backup power generator
- EKG/ECG – Electrocardiogram
- 24 hour emergency phone number
- Crash cart
- Dry Ice on site
- Oxygen tank
- Daily FedEx, UPS, and USPS pickup
- On-site Records Storage, with long-term off-site records storage
- Large conference room available for monitors.
- Fax and copy machines available at any time to monitors
- High-speed internet for patients, monitors, and guests-wired or wireless
- Patient waiting area
ELI LILY
AACI
This critical trial explores Donanemab’s potential in preventing the progression of early Alzheimer’s disease by targeting amyloid plaques in the brain. This N3pG antibody aims to halt or slow cognitive decline. This study holds promise for early intervention in Alzheimer’s disease’s progression.
FDA APPROVED
EISAI
Lecanemab
The Lecanemab antibody targets amyloid-beta plaques in the brain to potentially slow the progression of Alzheimer’s disease. This study examines its impact on cognitive function over 18 months, with an extension phase to monitor long-term safety and effects.
FDA APPROVED
NOVARTIS
Fingolimod
This study evaluated patients with relapsing multiple sclerosis treated with Fingolimod (KESIMPTA). This was to further explore the incidence of selected safety-related outcomes and to further monitor the overall safety profile of Fingolimod under conditions of routine medical practice.
FDA APPROVED